These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 33978871)

  • 1. Othello syndrome in Parkinson's disease: a systematic review and report of a case series.
    De Michele G; Palmieri GR; Pane C; Dello Iacovo CDP; Perillo S; Saccà F; De Michele G; De Rosa A
    Neurol Sci; 2021 Jul; 42(7):2721-2729. PubMed ID: 33978871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Othello syndrome in patients with Parkinson's disease.
    Georgiev D; Danieli A; Ocepek L; Novak D; Zupancic-Kriznar N; Trost M; Pirtosek Z
    Psychiatr Danub; 2010 Mar; 22(1):94-8. PubMed ID: 20305599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Othello syndrome in Parkinson's disease: A diagnostic emergency of an underestimated condition.
    El Otmani H; Sabiry S; Bellakhdar S; El Moutawakil B; Abdoh Rafai M
    Rev Neurol (Paris); 2021 Jun; 177(6):690-693. PubMed ID: 33276961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: a case series.
    Poletti M; Lucetti C; Baldacci F; Del Dotto P; Bonuccelli U
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1290-2. PubMed ID: 25277963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Othello syndrome in Parkinson disease patients without dementia.
    Cannas A; Solla P; Floris G; Tacconi P; Marrosu F; Marrosu MG
    Neurologist; 2009 Jan; 15(1):34-6. PubMed ID: 19131855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study.
    Poletti M; Perugi G; Logi C; Romano A; Del Dotto P; Ceravolo R; Rossi G; Pepe P; Dell'Osso L; Bonuccelli U
    Mov Disord; 2012 Nov; 27(13):1679-82. PubMed ID: 23150469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delusional Jealousy (Othello Syndrome) in 67 Patients with Parkinson's Disease.
    Kataoka H; Sugie K
    Front Neurol; 2018; 9():129. PubMed ID: 29563893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.
    Kiziltan G; Ozekmekçi S; Ertan S; Ertan T; Erginöz E
    J Neurol; 2007 Apr; 254(4):448-52. PubMed ID: 17401525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
    Dafsari HS; Martinez-Martin P; Rizos A; Trost M; Dos Santos Ghilardi MG; Reddy P; Sauerbier A; Petry-Schmelzer JN; Kramberger M; Borgemeester RWK; Barbe MT; Ashkan K; Silverdale M; Evans J; Odin P; Fonoff ET; Fink GR; Henriksen T; Ebersbach G; Pirtošek Z; Visser-Vandewalle V; Antonini A; Timmermann L; Ray Chaudhuri K;
    Mov Disord; 2019 Mar; 34(3):353-365. PubMed ID: 30719763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
    Zoldan J; Friedberg G; Weizman A; Melamed E
    Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
    [No Abstract]   [Full Text] [Related]  

  • 12. Visual hallucinations in photographs in Parkinson's disease.
    Vaou O; Saint-Hilaire M; Friedman J
    BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23704424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early dopaminergic drug-induced hallucinations in parkinsonian patients.
    Goetz CG; Vogel C; Tanner CM; Stebbins GT
    Neurology; 1998 Sep; 51(3):811-4. PubMed ID: 9748031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between temperament and depression in Parkinson's disease patients under dopaminergic treatment.
    Dogan B; Akyol A; Memis CO; Sair A; Akyildiz U; Sevincok L
    Psychogeriatrics; 2019 Jan; 19(1):73-79. PubMed ID: 30141277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
    Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho J;
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):30-37. PubMed ID: 30361296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuropsychiatric disorders in Parkinson's disease].
    Noé-Sebastián E; Irimia-Sieira P; Pomares-Arias E; Martínez-Vila E; Luquin-Piudo MR
    Rev Neurol; 2001 Apr 1-15; 32(7):676-81. PubMed ID: 11391498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.